Tuesday, March 31, 2009

Peregrine Pharmaceuticals Awarded New U.S. Patent Further Strengthening Its Anti-Phospholipid Patent Portfolio

Peregrine Pharmaceuticals, Inc. today reported the issuance of a U.S. patent that further strengthens the company's intellectual property leadership in the field of phospholipid-targeting agents for the treatment of life-threatening diseases.

The details can be read here.

No comments: